Sight Sciences (NASDAQ:SGHT) Posts Earnings Results, Beats Estimates By $0.10 EPS

Sight Sciences (NASDAQ:SGHT) released its quarterly earnings data on Wednesday. The company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.10, FiscalAI reports. Sight Sciences had a negative return on equity of 52.34% and a negative net margin of 46.83%.The company had revenue of $23.39 million for the quarter, compared to analyst estimates of $21.72 million.

Here are the key takeaways from Sight Sciences’ conference call:

• Positive Sentiment: Second-quarter revenue increased 20% year over year to $23.4 million, driven by growth in both interventional glaucoma and dry eye; net loss improved 63% to $4.4 million.
• Positive Sentiment: Management raised 2026 revenue guidance to $88 million–$92 million and lowered adjusted operating expense guidance to $92 million–$94 million, citing stronger execution and continued expense discipline.
• Positive Sentiment: TearCare dry-eye revenue nearly doubled sequentially to a record $2.7 million, with ordering accounts rising to 176 and covered lives increasing to approximately 14.5 million. The company expects reimbursement-related momentum to build in the second half, although additional payer wins are not included in guidance.
• Positive Sentiment: OMNI glaucoma revenue grew 8% year over year, while active accounts reached a record and utilization recovered to its highest level since late 2024. Aetna added roughly 25 million covered lives, and the company plans a staged OMNI Ultra rollout beginning before its full launch at the AAO meeting and broader adoption in 2027.
• Negative Sentiment: Cash declined to $79.8 million after a $5.4 million Alcon litigation-related success-fee payment; the company also faces ongoing legal uncertainty as Alcon appeals the judgment, which included approximately $55 million in damages and interest plus future royalties.

Sight Sciences Price Performance

NASDAQ:SGHT traded up $1.54 during mid-day trading on Thursday, reaching $7.09. The stock had a trading volume of 778,182 shares, compared to its average volume of 270,707. The stock has a market capitalization of $385.77 million, a P/E ratio of -9.99 and a beta of 2.38. The firm has a 50 day moving average price of $5.14 and a two-hundred day moving average price of $4.90. The company has a debt-to-equity ratio of 0.68, a quick ratio of 5.48 and a current ratio of 5.86. Sight Sciences has a one year low of $3.19 and a one year high of $9.24.

Insiders Place Their Bets

In other Sight Sciences news, CTO David Badawi sold 7,418 shares of the stock in a transaction that occurred on Monday, July 6th. The stock was sold at an average price of $5.51, for a total value of $40,873.18. Following the completion of the sale, the chief technology officer owned 1,982,872 shares in the company, valued at approximately $10,925,624.72. This trade represents a 0.37% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO James Rodberg sold 6,902 shares of the business’s stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $5.36, for a total value of $36,994.72. Following the transaction, the chief financial officer directly owned 224,037 shares in the company, valued at $1,200,838.32. This trade represents a 2.99% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 58,566 shares of company stock worth $318,827. 30.40% of the stock is currently owned by company insiders.

Institutional Trading of Sight Sciences

Several large investors have recently bought and sold shares of SGHT. BNP Paribas Financial Markets grew its stake in shares of Sight Sciences by 99.8% in the third quarter. BNP Paribas Financial Markets now owns 7,579 shares of the company’s stock worth $26,000 after acquiring an additional 3,785 shares during the last quarter. O Shaughnessy Asset Management LLC purchased a new position in shares of Sight Sciences in the 4th quarter worth about $81,000. Tower Research Capital LLC TRC raised its position in shares of Sight Sciences by 32.7% in the 2nd quarter. Tower Research Capital LLC TRC now owns 11,665 shares of the company’s stock worth $48,000 after purchasing an additional 2,875 shares during the last quarter. The Manufacturers Life Insurance Company bought a new position in Sight Sciences in the 4th quarter worth about $96,000. Finally, Kemnay Advisory Services Inc. purchased a new stake in Sight Sciences during the 4th quarter valued at about $107,000. 55.51% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on SGHT shares. UBS Group increased their price target on shares of Sight Sciences from $7.00 to $8.00 and gave the stock a “buy” rating in a report on Thursday. Weiss Ratings downgraded shares of Sight Sciences from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, May 11th. Finally, Citigroup increased their price objective on Sight Sciences from $5.15 to $6.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 8th. Five research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $7.88.

Trending Headlines about Sight Sciences

Here are the key news stories impacting Sight Sciences this week:

• Positive Sentiment: UBS upgraded SGHT to Buy and raised its price target to $8 from $7, signaling increased confidence in the company’s outlook. Benzinga report
• Positive Sentiment: Second-quarter results beat expectations: Sight Sciences reported an adjusted loss of $0.08 per share, better than the $0.15-$0.18 consensus loss, while revenue of $23.39 million exceeded estimates of approximately $21.72 million. The quarterly loss also narrowed from $0.23 per share a year earlier. Sight Sciences Q2 results
• Positive Sentiment: Management raised full-year 2026 revenue guidance to $88 million-$92 million, above the roughly $86.1 million analyst consensus, and reduced adjusted operating-expense guidance. Sight Sciences financial results release
• Positive Sentiment: Aetna added coverage for the OMNI and SION systems for eligible patients with mild-to-moderate open-angle glaucoma. Broader reimbursement could support physician adoption and future procedure volumes. Aetna coverage announcement
• Positive Sentiment: The FDA cleared the OMNI Ultra Surgical System, a next-generation minimally invasive glaucoma device featuring single-pass canaloplasty and TruSync Plus technology. The U.S. commercial launch remains planned for the fourth quarter of 2026, creating a potential new product catalyst. OMNI Ultra FDA clearance
• Negative Sentiment: Despite the earnings beat, Sight Sciences remains unprofitable, with a negative net margin and analysts forecasting a full-year loss. Commercial execution, physician adoption and competition remain risks for OMNI Ultra.
• Negative Sentiment: Recent insider-trading data shows sales but no purchases by company insiders over the past six months, a potentially cautious signal for investors.

About Sight Sciences

Sight Sciences, Inc is a medical device company focused on developing and commercializing minimally invasive treatments for chronic eye diseases. The company’s flagship products include the OMNI® Surgical System, designed to address multiple points of resistance in the eye’s natural drainage pathways to lower intraocular pressure in glaucoma patients, and the TearCare® System, a wearable device for treating meibomian gland dysfunction and dry eye disease through targeted thermal pulsation therapy.

Since its founding in 2012 and subsequent listing on the NASDAQ under the ticker SGHT, Sight Sciences has pursued a strategy of combining research-driven product development with a direct sales force model.